|
PubHealth.info®
(a subsidiary of
PakMed) presents scientific information mainly
based on abstracts of articles published on a variety of public health issues/topics,
particularly encompassing
population planning, disease prevention, maternal and child health,
and communicable and
non-communicable diseases (like HIV AIDS, malaria, etc) that are
affecting a significant portion of population in developing and
developed
countries. Here you can find abstracts of articles published on a variety of public health
topics under category "Contraception
(Birth Control) and Family Planning".
Contraception (birth control)
is a regimen of one or more actions, devices, or medications followed in
order to deliberately prevent or reduce the likelihood of a woman
becoming pregnant or giving birth. Therefore contraception is the
utilization of various and sundry surgical procedures, devices,
practices, agents, or drugs with the intention of preventing conception
or impregnation (pregnancy). Methods and intentions typically termed
birth control may be considered a pivotal ingredient to family
planning. Birth control is a controversial political and ethical
issue in many cultures and religions, and although it is generally less
controversial than abortion specifically. |
|
|
| CATEGORY: |
Contraception (Birth Control) and Family Planning |
| Safety of combined oral contraceptive pills [letter] |
| Lancet. 1996 Feb 24;347(9000):548-9. |
| Some of your correspondents wonder if there are any plausible metabolic changes that can explain why users of OCs |
| containing desogestrel or gestodene are at higher risk of thromboembolic events than users of OCs containing |
| norgestrel. Since obvious selection bias seems to have been eliminated one possibility is that the higher high- |
| density lipoprotein cholesterol (HDL-C) level, associated with higher triglycerides (TG), seen in users of the new OCs |
| is not an optimum metabolic change. The parallel increase in HDL-C and TG is related to the impact of ethinyl |
| estradiol on liver metabolism, largely through a decrease in hepatic lipase activity, and is associated with an |
| increase in estrogen-dependent synthesis of several proteins such as sex-hormone-binding globulin |
| angiotensinogen and, more important, coagulation factors. These liver disturbances induced by ethinyl estradiol are |
| partly reduced by the antiestrogenic effect of the associated progestagen but significantly more by norgestrel than by |
| desogestrel. For example, the mean increase in TG is about two-fold higher when desogestrel instead of norgestrel |
| is associated with ethinyl estradiol daily dose, and the frequency of coagulation disturbances may also be twice as |
| high. To predict favorable or unfavorable metabolic changes with estrogen/progestagen formulations in one |
| individual, TG changes might be useful. Because there is still no easy test of the potential coagulation/fibrinolysis |
| imbalance, TG may be used as a cheap and fast (1-2 months) individual marker of liver metabolic disturbances |
| induced by steroids. (PubHealth.info Document ID: CONT2T 2090-06) |
| PubHealth.info NOTE: The author(s) of this article titled, "Safety of combined oral contraceptive pills [letter]", is(are) |
| de Lignieres B. The source of this article is "Lancet. 1996 Feb 24;347(9000):548-9.". This article was published in |
| 1996 in English language(s). (PubHealth.info® Document ID: CONT2T 2090-06. All rights reserved with |
| PubHealth.info) PIN: 7090 |
|
|
|
© Copyrights PubHealth.info®,
an information portal on public health. All rights
reserved.
This page is optimized to be viewed by
Java script enabled Microsoft®
Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels. |
